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Abstract 
 
There have been significant changes in the staging, classification and grading of renal cell 
neoplasia in recent times. Major changes have occurred in our understanding of extra-renal 
extension by renal cell cancer and how gross specimens must be handled to optimally 
display extra-renal spread. Since the 1981 World Health Organization (WHO) classification 
of renal tumors, in which only a handful of different entities were reported, many new 
morphological types have been described in the literature, resulting in 50 different entities 
reported in the 2004 WHO classification. Since 2004, further new entities have been 
recognized and reported necessitating an update of the renal tumor classification. There 
have also been numerous grading systems for renal cell carcinoma with Fuhrman grading, 
the most widely used system. In recent times, the prognostic value and the applicability of 
the Fuhrman grading system in practice has been shown to be, at best, suboptimal. To 
address these issues and to recommend reporting guidelines, the International Society of 
Urological Pathology (ISUP) undertook a review of adult renal neoplasia through an 
international consensus conference in Vancouver in 2012. The conduct of the conference 
was based upon evidence from the literature and the current practice amongst recognized 
experts in the field. Working groups selected to deal with key topics evaluated current data 
and identified points of controversy. A pre-meeting survey of the ISUP membership was 
followed by the consensus conference at which a formal ballot was taken on each key issue. 
A 65% majority vote was taken as consensus. This review summarizes the outcome and 
recommendations of this conference with regards to staging, classification and grading of 
renal cell neoplasia. Copyright: The Authors. 
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Introduction 
 
 
Renal cancer is one of the most common 
visceral malignancies with a significant rate 
of cancer related deaths in both males and 
females (1, 2). While surgical removal is the 
gold standard treatment for localized 
kidney cancer, many targeted therapies 
have been recently introduced for the 
treatment of metastatic renal cell cancer (3-
5). Accurate diagnosis, grading and staging 
are crucial in the management of these 
patients, both to improve outcome as well 
as to allow for accurate prognostication. 
Staging of renal cell cancer is one of the 
most important predictors of prognosis and 
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among staging criteria it has recently been 
recognized that renal sinus invasion is the 
most common route of extra-renal spread 
(6, 7). Bonsib et al. (8) showed > 90% of 
clear cell renal cell carcinoma (RCC)   ≥ 
7cm in diameter to have invaded the renal 
sinus.  In a further study, Thompson et al. 
(9) examined additional tissue from 
nephrectomy specimens from patients with 
pT1 disease who had died of RCC.  Renal 
sinus invasion was found in 14 (42%) of 
these cases and they compared these 
findings with a matched set of 33 patients 
who had not died of RCC. In this latter 
group renal sinus invasion was seen in 
only 2 (6%) of cases. Appropriate sampling 
of a kidney tumor, including adequate 
sampling of the renal sinus has been 
shown to be extremely important for the 
correct staging of kidney tumors (8, 10). In 
addition to recognizing this, the 7th edition 
of the TNM staging system of the 
International Union Against 
Cancer/American Joint Commission on 
Cancer/ (UICC/AJCC) introduced several 
changes to the staging system of RCC (11, 
12). In parallel with this renal tumor 
classification has undergone major changes 
in the last three decades, with novel 
morphotypes being added to successive 
classification systems (13-15).  Also during 
this time several grading systems for RCC 
have been proposed, of which the Fuhrman 
grading system had achieved most 
popularity (16). In recent years, the value of 
this system has been questioned, not only 
with regards to its applicability in practice, 
but also with regards to its value as a 
prognostic marker (17- 19).  
 
In order to address these issues the 
International Society of Urological 
pathology (ISUP), convened a consensus 
conference to produce guidelines and made 
recommendations regarding the 
handling/sampling and staging, 
classification and grading, of adult kidney 
RCC based on current practice and 
evidence from the literature (20-24). Here 
we present a summary the results of this 
ISUP consensus meeting.  
 
Handling and staging of RCC 
 
Appropriate handling is clearly the first 
step toward accurate diagnosis and staging 
of RCC and these issues were considered 
by an expert group convened prior to the 
conference. After deliberation by the 
conference delegates, it was recommended 
that the initial sampling section should be 
along the long axis of the kidney. It was 
considered that this could be in the mid 
lateral plane of the kidney or through the 
collecting system or vascular system. It was 
agreed that the optimal method to identify 
renal sinus venous invasion is to open the 
kidney along probes placed in large venous 
channels. It was further agreed that margin 
involvement should be assessed by inking 
suspicious areas, the perinephric fat 
margin and hilum of radical nephrectomy 
specimens or the renal parenchymal 
resection margin and perinephric margin of 
partial nephrectomy specimens. At present 
there is no information in the literature as 
to how best demonstrate perinephric fat 
invasion and it was agreed that the fat 
overlying the tumor should be kept intact, 
with multiple perpendicular cuts made, 
with a view to sampling suspicious areas. 
 
Tumor measurements 
 
Tumor size is an important determinant of 
the UICC/AJCC TNM pathologic stage (11, 
12) and correlates with perinephric fat 
extension, renal sinus invasion, prognosis 
and metastatic potential. There are several 
confounding factors in the estimation of 
tumor size. Retrograde venous invasion, 
renal vein and vena cava tumor, which can 
invade through the venous wall to achieve 
confluence, can cause problems with tumor 
size measurements. There is currently no 
guidance in the literature as to how size 
should be measured and whether or not a 
renal vein thrombus should be included in 
the measurement of the main tumor mass. 
It was agreed that after bivalving the 
kidney, multiple further sections (usually 
perpendicular) should be examined to 
ascertain the maximum tumor dimension. 
Although areas of contiguous involvement 
of perinephric fat and renal sinus tissue 
should be included in the tumor 
measurement, satellite nodules should not. 
There was consensus that the tumor 
measurements should not include a renal 
vein or caval thrombus. In cases with 
multiple tumors, there was near consensus 
(survey 62%) that all tumors up to some 
designated maximum (eg.5) should be 
measured, with fewer participants 
Samaratunga et al.                                                                                      Advances in renal neoplasia classification  
                                                                                     
JKCVHL 2014; 1(3):26-39 http://jkcvhl.com  28 
 
 
 
 
Figure 1A. Rounded nodules in the renal sinus indicate sinus vascular involvement. 
 
 
in favour of providing a measurement for 
the largest two tumors, as well as a range 
for all other tumors present.  
 
Gross examination for lymph nodes 
 
While there has been a suggestion that 
both peri-renal and hilar fat should be 
dissected in order to detect lymph nodes 
(25), it has also been claimed that 
palpation and dissection of the renal hilar 
area only is sufficient (26).  Mehta et al. 
(27) examined the entire hilar tissue for 
histology and found that 80% of grossly 
visible lymph nodes were positive for 
tumor, whereas microscopic lymph nodes 
were all benign.  
 
In view of this it would appear that 
examining the grossly evident lymph nodes 
only is sufficient and there was consensus 
that dissection of the hilar fat, for the 
purpose of identifying lymph nodes, is 
sufficient. 
 
Sampling tumor 
 
Previous sampling recommendations have 
been to take at least one block/cm of 
greatest dimension of tumor (26, 28). Areas 
of different appearance or consistency and 
blocks to demonstrate tumor relationship 
with peri-renal fat, renal sinus, renal pelvis 
and adrenal gland should also be taken. 
There was consensus that sampling should 
follow this general guideline of sampling 
with a minimum of three blocks. Multiple 
tumors are commonly found in hereditary 
syndromes such as von Hippel-Lindau 
disease, hereditary papillary RCC, 
Tuberous sclerosis and Birt-Hogg-Dube 
syndrome (29-31). Multiple tumors also 
occur with oncocytosis, acquired cystic 
kidney disease and with papillary RCC (32, 
33). Multifocality in sporadic RCC is rare. It 
is extremely uncommon to have >5 tumors 
in one kidney and in such instances 
sampling issues are not addressed in the 
literature. There was consensus that in 
cases with multiple tumors, sampling  
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Figure 1B. Tumor grossly involving the renal vein is usually visible to the naked eye. A tumor 
thrombus typically expands the renal vein. The renal vein margin (arrow) often retracts back from the 
tumor thrombus when vein clamps are removed. 
 
 
should include the 5 largest tumors at a 
minimum.  
 
Sampling the renal sinus  
 
The renal sinus is the fatty tissue 
compartment that lies between renal 
parenchyma and the pelvi-calyceal system. 
This is a complex structure with the 
vascular system being anterior to the pelvi-
calyceal system and the sinus extending 
anteriorly and posteriorly within the kidney 
(7). Veins entering the renal sinus have a 
smooth muscle media of variable thickness. 
Gross recognition of renal sinus 
involvement is often not difficult and 
rounded nodules in the renal sinus outside 
the main tumor indicate sinus vein 
invasion (Fig. 1A).  Sinus fat invasion 
occurs when intravenous tumor invades 
through the media (33), however, in some 
cases tumor bulging into the sinus can be 
difficult to interpret. Recommendations for  
 
sampling have varied with protocols 
ranging from sampling of the entire 
interface to 2-3 blocks (6, 7, 34, 35). At the 
meeting there was consensus that when 
invasion of the renal sinus is uncertain, at 
least three blocks of the interface should be 
taken. If invasion is grossly evident or 
obviously not present (small peripheral 
tumor) only 1 block is needed to confirm 
the gross impression. 
 
Sampling renal vein and vena cava 
 
Tumor grossly involving the renal vein is 
usually visible to the naked eye. A tumor 
thrombus typically expands the renal vein 
(Fig. 1B) and may or may not be adherent 
to the renal vein wall. If the surgical margin 
is clamped, there is a tendency for the 
renal vein margin to retract back from the 
tumor thrombus when the clamps are 
removed. There was near consensus that 
the actual margin and additional sections 
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Figure 2A. Carcinoma in contact with renal sinus fat indicates renal sinus invasion. 
 
 
of the tumor thrombus should be sampled, 
particularly in areas where tumor is 
adherent to the wall.  
 
Tumor invading into the vena cava wall has 
prognostic significance (35). In the 7th 
edition of the UICC/AJCC staging 
classification, tumor extending into the 
vena cava above the diaphragm or invading 
vena cava wall is classified as pT3c. In 
cases where a caval thrombus is present 
below the diaphragm, identification of 
invasion of the caval wall alters the staging 
category from pT3b to pT3c (12), thus 
impacting adversely on prognosis. It is 
therefore mandatory that adequate sections 
be examined, so as not to overlook this. 
When a specimen is submitted separately 
as a “caval thrombus” there was consensus 
that two or more sections must be taken to 
look for presence of tumor invading the 
caval wall. 
 
Sampling of normal renal parenchyma 
 
Since a kidney removed for neoplastic 
disease may also have concurrent non-
neoplastic renal pathology including 
glomerular, tubulointerstitial and vascular 
disease, it was recommended that normal 
parenchyma with tumor, and normal 
parenchyma distant from the tumor be 
sampled. 
 
Renal sinus invasion 
 
In the renal sinus, large veins are thought 
to become involved before small veins and 
as such small vein involvement usually 
implies large vein involvement. The renal 
sinus has rich venous anastomoses, 
therefore any venous involvement is likely 
to have metastatic risk. The majority of 
participants in the pre-meeting survey 
agreed that contact with renal sinus fat, 
(Fig. 2A) or loose connective tissue, clearly 
beyond the renal parenchyma indicated 
renal sinus invasion. Large sinus veins, 
including segmental branches of renal vein 
have marked variability in amount of 
smooth muscle and it was agreed that, if 
there are any endothelial lined spaces 
containing tumor within the renal sinus, 
regardless of size, this must also be 
considered renal sinus invasion (pT3a) (Fig. 
2B). 
 
Perinephric fat invasion  
 
Perinephric fat is present outside the renal 
capsule within the confines of the Gerota 
fascia.  Since many RCC arise in the renal 
cortex they may protrude into the 
perinephric fat, distorting the renal 
contour.  The presence of a smooth, convex 
outer surface, even if tumor protrudes well 
into the perinephric fat, does not constitute 
perinephric fat invasion (Fig. 3A). When 
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Figure 2B. Carcinoma within vascular channels within the renal sinus, regardless of size is also 
considered renal sinus invasion. 
 
 
RCC invades through the renal capsule 
into perinephric fat, there is loss of the 
smooth convex outer contour, with nodules 
or irregular tumor masses protruding into 
the perinephric fat (Fig. 3B).  
Microscopically, perinephric fat invasion is 
confirmed when there is tumor touching fat 
or extending as irregular tongues into 
perinephric tissues, with or without 
desmoplasia (Fig. 3C). 
 
Venous invasion 
 
There was agreement amongst participants 
in the survey that, to diagnose renal vein 
margin positivity, there must be 
microscopically confirmed adherent tumor 
at the actual margin. If there is microscopic 
infiltration of the inferior vena cava by 
tumor, this is considered to be caval 
involvement. Tumor in vascular channels 
of any size in the renal sinus, including 
segmental branches of renal vein, must be 
reported as this is considered indicative of 
pT3a staging category. 
 
Adrenal gland involvement 
 
In the current UICC/AJCC TNM staging 
classification (11) direct invasion of the 
adrenal gland is considered to be pT4 
disease. This is a significant change from 
the 2002 UICC/AJCC TNM classification, 
in which adrenal gland invasion was 
considered to be pT3 disease. This change 
is based on reports that adrenal gland 
involvement has a significantly worse 
prognosis than that of perinephric fat 
invasion (36, 37). In view of this the 
adrenal gland should be carefully examined 
to assess whether it is involved by 
carcinoma, and if so, whether this is by 
direct invasion (pT4) or metastatic spread 
needs to be assessed (Fig. 4). 
 
Renal tumor classification (ISUP 
Vancouver classification of renal 
neoplasia)  
 
There were a number of recommendations 
with regards to modifications to the 2004 
World Health Organization (WHO) 
classification of renal tumors. Five distinct 
and novel epithelial malignancies were 
added to the classification. These are 
tubulocystic RCC (38), acquired cystic 
disease-associated RCC (39), clear cell 
(tubulo) papillary RCC (40), 
microphthalmia transcription factor family 
(MiTF) translocation RCC (41) and 
hereditary leiomyomatosis RCC syndrome-
associated RCC (42). There was agreement 
that, as reports of most of these new 
entities contained too few cases to enable 
prognostication; this should not be 
formulated at this time. 
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Figure 3A. If the outer surface of the tumor is smooth and convex, even if tumour protrudes well into 
the perinephric fat, it is not considered perinephric invasion. 
 
 
An exception to this was clear-cell (tubulo) 
papillary RCC which was considered to be 
a low-grade malignancy with a very 
favorable prognosis. The position of 
succinate dehydrogenase B deficiency-
associated RCC (43) ALK translocation 
associated RCC (43, 44) and thyroid-like 
follicular RCC (45) in the new classification 
was considered. It was agreed that, while 
these entities was sufficiently well defined 
to enable identification, further reports 
were necessary to permit a clear 
understanding of the nature and behavior 
of these tumors. As such these tumors 
were considered emerging or provisional 
new entities and were not included in the 
Vancouver classification.  
 
New concepts relating to recognized tumors 
included considering multicystic clear cell 
RCC as a neoplasm of low malignant 
potential as to date it has shown to have a 
universally favourable outcome (46). It was 
agreed that subtyping of papillary RCC 
(type 1, type 2 and other) was of value, 
however, oncocytic papillary RCC was not 
accepted as a distinctive entity in the new 
classification. Hybrid oncocytic 
chromophobe tumor (HOCT) was, for the 
time being, included as a subtype in the 
category of chromophobe RCC (47, 48).  
HOCT is an apparently indolent tumor that 
occurs in 3 distinct clinical settings: Birt- 
Hogg- Dube syndrome, renal oncocytosis 
and sporadic neoplasm.  
 
Advances in our understanding of the 
behavior of angiomyolipomas, including 
epithelioid and cystic variants, were 
discussed. It was agreed that epithelioid 
angiomyolipoma should be classified 
according to presence or absence of atypia, 
as this would more accurately predict 
outcome of these tumors than the 
recognition of the presence of an epithelioid 
morphology without further qualification.  
 
The relationship between cystic nephroma 
and mixed epithelial stromal tumor of 
kidney was discussed with a consensus 
that these tumors represent the same 
spectrum of neoplasia.  Finally, synovial 
sarcoma was removed from the mixed  
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Figure 3 B. When RCC invades through the 
renal capsule into the perinephric fat, there is 
loss of the smooth convex outer contour, with 
nodules or irregular tumor masses protruding 
into the perinephric fat.  
 
 
epithelial and mesenchymal category and 
placed within the sarcoma group. The new 
classification agreed to at the meeting 
should be cited as the International Society 
of Urological Pathology Vancouver 
Classification of Renal Neoplasia.  
 
ISUP Grading Classification 
 
There have been numerous grading 
systems for RCC, of which the Fuhrman 
grading system has achieved most 
popularity in clinical practice. (16, 49-51). 
Despite this, the value of this system in 
assessment of prognosis has been 
questioned (17, 19). Several studies have 
found that the Fuhrman grading system 
has prognostic significance only when the 
data are grouped (e.g. grade 1+ grade 2 
versus grade 3+ grade 4), which effectively 
reduces the grading system to a 2 tier 
system. These results are somewhat similar 
to Fuhrman’s original report in which grade 
2 and grade 3 tumors were found to have 
similar survival with combined grades 2 
and 3 tumors, differing significantly in 
outcome from grade 1 and grade 4 tumors. 
This reduces the value of this system as 
the majority of RCC fall within the 2 central 
Figure 3C. Tumor extending as irregular 
tongues into perinephric tissues with or without 
desmoplasia is considered perinephric fat 
invasion. 
 
grading categories. Another problem is that 
Fuhrman’s validating study was based on a 
mixed series of RCC, which introduced an 
uncontrolled variable in the outcome 
studies based upon these data.  
 
The application of the Fuhrman grading 
system in practice is complicated as there 
are three separate parameters within each 
grade, and involves the simultaneous 
assessment of nuclear size, nuclear shape 
and nucleolar prominence. There are no 
directions as to how these parameters 
should be stratified if they individually 
provide conflicting information. It is not 
surprising that this grading system has 
been shown to have poor to moderate inter-
observer reproducibility and this is likely to 
be due to the subjective nature of the 
grading process (17). To compensate for 
this, many pathologists using the Fuhrman 
grading system have utilized nucleolar 
grade alone, which is not the 
recommendation of the Fuhrman grading 
system.  
 
Recent studies have shown that nucleolar 
grade alone is sufficient to define grades 1 
to 3 for clear cell and papillary RCC and 
that this provides outcome prediction 
superior to that of Fuhrman grading. In 
these studies, grade was based upon the 
single high power field showing the highest 
grade (52, 53). These observations have 
been validated in independent survival 
studies (54, 55).  There was also an 
agreement that the presence of rhabdoid or 
sarcomatoid morphology within any of the
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Figure 4. When the adrenal gland is involved it must be established whether it is direct invasion (pT4) 
or metastatic spread (pM1). In this example, both appear to be present. 
 
 
morphotypes of renal cell carcinoma 
represents a form of tumor 
dedifferentiation. The prognosis of these 
tumors is similar to that associated with 
presence of extreme nuclear pleomorphism 
or tumor giant cells (56, 57). These 
combined observations were incorporated 
into a novel grading classification for renal 
cell carcinoma to be known as ISUP 
Grading Classification for renal cell 
carcinoma (Table 1) (58).  
 
In this classification, grades 1-3 were 
based on nucleolar prominence, while 
grade 4 was defined as tumors with highly 
pleomorphic tumor giant cells or the 
presence of sarcomatoid and/or rhabdoid 
morphology. There was consensus that this 
classification is recommended for papillary 
and clear cell renal cell carcinoma. It was 
also agreed that as no current grading 
system provided independent prognostic 
information for chromophobe RCC (59).  
These tumors should not be graded. In 
addition to its role as a component of 
grading, it was agreed that sarcomatoid 
differentiation should be reported 
separately. As a minimum percentage was 
not a requirement for diagnostic purposes 
it was concluded that it was not necessary 
to report the percentage of sarcomatoid 
differentiation within individual tumors. 
Similarly for tumors with rhabdoid 
morphology, it was agreed that it was 
unnecessary to report the percentage of 
rhabdoid tumor present. For both of these 
dedifferentiation patterns it is, however; 
necessary to report the underlying primary 
morphotype. In cases where no primary 
tumor morphotype is apparent, these 
should be reported as undifferentiated 
carcinoma with a sarcomatoid/rhabdoid 
component.  
Other prognostic factors 
In addition to tumor grading, numerous 
prognostic factors have been investigated 
for RCC. Prognostic parameters that, 
according to the consensus conference, 
should be routinely reported are tumor 
necrosis and tumor morphotype (22). 
Tumor necrosis was considered to be of 
prognostic significance and it was agreed 
that assessment of this should be based on  
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Table 1.  The International Society of Urological Pathology grading classification for renal 
cell carcinoma (58, 60) 
 
Grade 1 
 
Tumor cell nucleoli invisible or small and basophilic at 400 x 
magnification 
 
Grade 2 
 
Tumor cell nucleoli conspicuous at 400 x magnification but 
inconspicuous at 100 x magnification 
 
Grade 3 
 
Tumor cell nucleoli eosinophilic and clearly visible at 100 x 
magnification 
 
Grade 4 
 
Tumors showing extreme nuclear pleomorphism and/or containing 
tumor giant cells and/or the presence of any proportion of tumor 
showing sarcomatoid and/or rhabdoid dedifferentiation 
 
    
 
both macroscopic and microscopic 
examination. It was recommended that for 
clear cell RCC, the amount of necrosis 
should be recorded as a percentage of the 
sampled tumor. There was agreement that 
the main tumor morphotypes of RCC were 
of prognostic significance (60). In particular 
it was noted that clear cell RCC, stage for 
stage, has a worse outcome than either 
chromophobe or papillary RCC. There was 
also consensus that the subtyping of 
papillary renal cell carcinoma into types 1 
and 2 provides prognostic information. 
Given that there is no conclusive evidence 
as to the significance of intra-tumoral 
microvascular invasion as a prognostic 
parameter, there was consensus that at 
present, this should not be considered as a 
potential staging criterion. 
 
Conclusion 
 
In keeping with advances in knowledge of 
renal neoplasia, staging, classification and 
grading of RCC have undergone major 
changes in recent times. To reflect this, the 
ISUP undertook a review of adult renal 
neoplasia through an international 
consensus conference in Vancouver in 
2012. This review summarizes the 
guidelines and recommendations from this 
conference regarding handling/sampling, 
staging, classification and grading of 
kidney tumors. It is hoped that such 
advances in classification will enable 
pathologists to follow uniformity in 
reporting of this highly heterogeneous 
disease. 
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